Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by Addex Therapeutics Ltd. on June 25, 2026. The filing incorporates by reference the company's Unaudited Interim Condensed Consolidated Financial Statements (Exhibit 99.1) and Management's Discussion and Analysis (Exhibit 99.2) for the period ending June 25, 2026. The company is headquartered in Geneva, Switzerland, and files annual reports on Form 20-F.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the incorporated Exhibits 99.1 and 99.2, which are not included in the source text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. Investors must refer to the incorporated Management's Discussion and Analysis (Exhibit 99.2) for comparative operational and financial results.
Guidance, Outlook, and Risks
- Risk Factors: The company states its business faces significant risks that could materially adversely affect its financial condition and growth prospects. It directs investors to the risk factors in its Annual Report on Form 20-F for the year ended December 31, 2025.
- Forward-Looking Statements: The report contains forward-looking statements involving risks and uncertainties. Actual results may differ materially from anticipated results due to various factors described in SEC filings.
- Management Commentary: Specific guidance or outlook details are not present in the cover text and are located in the incorporated exhibits.
Investor Verification Checklist
- Review Exhibit 99.1 for specific interim financial figures (revenue, cash position, and burn rate).
- Examine Exhibit 99.2 for management's analysis of operational progress and financial condition.
- Consult the Annual Report on Form 20-F (filed May 15, 2026) for detailed risk factors referenced in this filing.
- Verify the content of the Press Release dated June 25, 2026 (Exhibit 99.3) for any material announcements.